

[Fig. 1]



TTK-A02
-9-462
a
TTK-A02
-9-630
b
TTK-A02
-9-593
c
TTK-A02
-9-719
d
TTK-A02
-9-142
e
TTK-A02
-9-146
f
TTK-A02
-9-564
g
TTK-A02
-10-462
h
TTK-A02
-10-542
i
TTK-A02
-10-661
j
+
−
1
2
3
4
5
6
7
8

[Fig. 2a-d]


a TTK-A02-9-462 #1




b TTK-A02-9-630 #7




c TTK-A02-9-593 #5



d TTK-A02-9-719 #5




[Fig. 2e-g]



e
TTK-A02-9-142 #5
IFN-γ (pg/ml)
3000
2500
2000
1500
1000
500
0
5.0
2.5
1.3
0.6
R/S ratio
+
-
f
TTK-A02-10-462 #2
IFN-γ (pg/ml)
3000
2500
2000
1500
1000
500
0
5.0
2.5
1.3
0.6
R/S ratio
+
-
g
TTK-A02-9-593 #5-27
IFN-γ (pg/ml)
2500
2000
1500
1000
500
0
5.0
2.5
1.3
0.6
R/S ratio
+
-

[Fig. 3]


a


TTK-A02-9-593
COS7
IFN-γ (pg/ml)
1600
1400
1200
1000
800
600
400
200
0
2.4 1.2 0.6 0.3 0.2
R/S ratio
A02 + TTK
A02
TTK

b


TTK-A02-9-593 #5
COS7
IFN-γ (pg/ml)
700
600
500
400
300
200
100
0
23.0 11.5 5.8 2.9 1.4 0.7
R/S ratio
A02 + TTK
A02
TTK


c


TTK-A02-9-593
tumor cell line
IFN-γ (pg/ml)
250
200
150
100
50
0
2.4 1.2 0.6 0.3 0.2
R/S ratio
H1650 (TTK+, A02+)
TE-1 (TTK+, A02-)
PC-3 (TTK+, A02-)


[Fig. 4]

Reference Data: The data of Endo Assays in Figs. of WO2008/102557.


WO08102557_Fig.8b



WO08102557_Fig.8c



WO08102557_Fig.8d



WO08102557_Fig.8e

